share_log

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

阿里拉姆制藥 | 8-K:Alnylam Pharmicals公佈2024年第三季度財務業績並重點介紹近期活動
美股SEC公告 ·  2024/10/31 08:16

牛牛AI助理已提取核心訊息

Alnylam Pharmaceuticals has announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release on October 31, 2024.The company has filed this information with the SEC via Form 8-K, with the financial results press release being furnished as Exhibit 99.1. The filing was authorized by Jeffrey V. Poulton, a senior executive of the company.
Alnylam Pharmaceuticals has announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release on October 31, 2024.The company has filed this information with the SEC via Form 8-K, with the financial results press release being furnished as Exhibit 99.1. The filing was authorized by Jeffrey V. Poulton, a senior executive of the company.
阿里拉姆制藥宣佈截至2024年9月30日的第三季度財務業績。該公告於2024年10月31日通過新聞稿發佈。公司已經通過8-K表格向證券交易委員會(SEC)提交了這條信息,財務業績的新聞稿作爲99.1號附錄提供。該文件由公司高級執行官Jeffrey V. Poulton授權。
阿里拉姆制藥宣佈截至2024年9月30日的第三季度財務業績。該公告於2024年10月31日通過新聞稿發佈。公司已經通過8-K表格向證券交易委員會(SEC)提交了這條信息,財務業績的新聞稿作爲99.1號附錄提供。該文件由公司高級執行官Jeffrey V. Poulton授權。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。